Floatz logo

VEMURAFENIB

Solid Tumour

Cancer Research UKSmall moleculePhase 2/3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Solid Tumour cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Henlix, Inc
Phase 2B
Atezolizumab
Genentech, Inc.
Phase 2/3B
ALECTINIB
Cancer Research UK
Phase 2/3B
Entrectinib
Cancer Research UK
Phase 2/3B
gsk1120212
Cancer Research UK
Phase 2/3B

View all 36 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →